scholarly journals Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus

2008 ◽  
Vol 198 (1) ◽  
pp. 65-76 ◽  
Author(s):  
Philip Wenzel ◽  
Andreas Daiber ◽  
Matthias Oelze ◽  
Moritz Brandt ◽  
Ellen Closs ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Rat Model ◽  
Hmg Coa Reductase ◽  
Streptozotocin Induced Diabetes ◽  
Coa Reductase

Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus

2007 ◽  
Vol 73 (9) ◽  
pp. 1367-1375 ◽  
Author(s):  
Andreas Schäfer ◽  
Daniela Fraccarollo ◽  
Christian Vogt ◽  
Ulrike Flierl ◽  
Melinda Hemberger ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Endothelial Function ◽  
Platelet Activation ◽  
Hmg Coa Reductase ◽  
Streptozotocin Induced Diabetes ◽  
Coa Reductase

scholarly journals Effects of Momordica Charantia Silver Nanoparticles on the expressions of Genes Associated With Lipid Metabolism and Nephrotoxicity in Streptozotocin-Induced Rats

2021 ◽  
Vol 37 (2) ◽  
pp. 126-133
Author(s):  
O.O Elekofehinti ◽  
M.O Akinjiyan
Keyword(s):  
Diabetes Mellitus ◽  
Silver Nanoparticles ◽  
Lipid Metabolism ◽  
Silver Nitrate ◽  
Nitrate Solution ◽  
Diabetic Control ◽  
Untreated Group ◽  
Rt Pcr ◽  
Hmg Coa Reductase ◽  
Coa Reductase

Hyperlipidemia and hyperglycemia have been implicated in diabetes mellitus (DM) leading to complications such as nephropathy. Medicinal plants like Mormodica charantia (MC) have been used in the treatment of DM over the years but little is known about their mechanisms of action. This study used biotechnology tools to investigate and compare the effects of M. charantia silver nanoparticles (MCSNPs) with M. charantia extract on expressions of genes linked with nephrotoxicity, lipid and glucose metabolisms using reverse-transcriptase polymerase chain reaction (RT-PCR) in streptozotocin-induced diabetic rats. The genes investigated include kidney injury molecule-1 (KIM-1), 3-hydroxyl, 3-methyl glutaryl_coA reductase (HMG-CoA reductase), peroxisome proliferator-activated receptor alpha and gamma (PPARα and PPARγ). Synthesis of MCSNPs was done using 1 mM concentration of aqueous silver nitrate solution at ratio 1:9 (v/v). Experimental rats were induced intraperitoneally with streptozotocin (65 mg/kg) and divided into six groups viz: diabetic control; normal control; silver nitrate (10 mg/kg); MCSNPs (50 mg/kg); Metformin (100 mg/kg) and M. charantia fraction (100 mg/kg). Sacrifice was done after 12 days of treatment and RT-PCR was then used to investigate gene expressions in liver and kidney tissues of the rats. The expression of HMG-CoA reductase gene was significantly upregulated (p<0.05) upon treatment with 50 mg/kg MCSNPs relative to the diabetic untreated group. M. charantia extracts and MCSNPs significantly upregulate (p<0.05) the expressions of PPAR-α and PPAR-γ compared to the diabetic control. Also, a significant (p<0.05) down-regulation of KIM-1 mRNA expression was observed in MCSNPs- treated group, relative to the diabetes untreated group. M. charantia silver nanoparticles could be a potent antidiabetic agent due to its potential to modulate genes associated with lipid metabolism and nephrotoxicity. Keywords: Medicinal plant; Diabetes Mellitus; Silver Nanoparticles; nephrotoxicity; gene expression

A preliminary study of the use of human adipose tissue-derived stem cells for the treatment of streptozotocin-induced diabetes mellitus in a rat model

2009 ◽  
Vol 19 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Mahmoud Abu-Abeeleh ◽  
Zuhair A. Bani Ismail ◽  
Khaled R. Alzaben ◽  
Sami A. Abu-Halaweh ◽  
Abdelkarim S. Aloweidi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Adipose Tissue ◽  
Rat Model ◽  
Human Adipose Tissue ◽  
Streptozotocin Induced Diabetes ◽  
Preliminary Study

Renal Effects of HMG-CoA Reductase Inhibition in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis

2006 ◽  
Vol 29 (3) ◽  
pp. 135-143 ◽  
Author(s):  
Dalibor Lecian ◽  
Hana Demova ◽  
Alena Lodererova ◽  
Jana Zdychova ◽  
Hana Kluckova ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Rat Model ◽  
Nitric Oxide Synthesis ◽  
Hmg Coa Reductase ◽  
Renal Effects ◽  
Coa Reductase

Effect of glucose or fructose feeding on cholesterol synthesis in diabetic animals

1985 ◽  
Vol 249 (5) ◽  
pp. G634-G641 ◽  
Author(s):  
K. R. Feingold ◽  
A. H. Moser
Keyword(s):  
Cholesterol Synthesis ◽  
Reductase Activity ◽  
Active Form ◽  
Diabetic Rats ◽  
Hepatic Cholesterol ◽  
Hmg Coa Reductase ◽  
Hepatic Cholesterol Synthesis ◽  
Streptozotocin Induced Diabetes ◽  
Intestinal Hypertrophy ◽  
Coa Reductase

Previous studies have demonstrated that cholesterol synthesis is increased twofold in the small intestines of rats with streptozotocin-induced diabetes. The purpose of the present study was to determine the effect of adding glucose or fructose to standard rat chow on cholesterol synthesis in control and diabetic rats. In control rats a 25% glucose or fructose diet fed for 21 days markedly inhibited hepatic cholesterol synthesis in the liver. In contrast, in diabetic animals only fructose inhibited hepatic cholesterol synthesis. In both control and diabetic animals the addition of these simple sugars to the diet did not markedly alter extrahepatic cholesterol synthesis. The enhancement of small intestinal cholesterol synthesis observed in diabetic animals was present regardless of the dietary manipulations. Further studies demonstrated that the addition of smaller concentrations of fructose (10%) to standard rat chow decreased hepatic cholesterol synthesis in both control and diabetic rats. Similarly the addition of fructose to the diet of control and diabetics for a period as short as 2 days was also sufficient to inhibit hepatic cholesterol synthesis. In both control and diabetic animals, fructose feeding decreased hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity but did not alter the percentage of HMG-CoA reductase in the active form. Finally, the intestinal hypertrophy and stimulation of intestinal cholesterogenesis that are characteristic of streptozotocin-induced diabetes occurred when either glucose or fructose was the sole caloric source.

Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan

2018 ◽  
Vol 7 (8) ◽  
pp. 800-810 ◽  
Author(s):  
Masayuki Hashiguchi ◽  
Junya Maruyama ◽  
Mikiko Shimizu ◽  
Daichi Takahashi ◽  
Tsuyoshi Shiga
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factor ◽  
Blood Glucose ◽  
Postmarketing Surveillance ◽  
Hmg Coa Reductase ◽  
High Blood Glucose ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Surveillance Database

Regulation of insulin sensitivity, insulin production, and pancreatic β cell survival by angiotensin-(1-7) in a rat model of streptozotocin-induced diabetes mellitus

Peptides ◽  
2015 ◽  
Vol 64 ◽  
pp. 49-54 ◽  
Author(s):  
Junhua He ◽  
Zhiming Yang ◽  
Huiyu Yang ◽  
Li Wang ◽  
Huilu Wu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Sensitivity ◽  
Cell Survival ◽  
Rat Model ◽  
Pancreatic Β Cell ◽  
Insulin Production ◽  
Β Cell ◽  
Streptozotocin Induced Diabetes

HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus

2004 ◽  
Vol 21 (9) ◽  
pp. 1020-1024 ◽  
Author(s):  
A. Nakashima ◽  
R. Nakashima ◽  
T. Ito ◽  
T. Masaki ◽  
N. Yorioka
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Loss ◽  
Hmg Coa Reductase ◽  
Prevent Bone Loss ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

scholarly journals Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis

2001 ◽  
Vol 89 (5) ◽  
pp. 415-421 ◽  
Author(s):  
Weihua Ni ◽  
Kensuke Egashira ◽  
Chu Kataoka ◽  
Shiro Kitamoto ◽  
Masamichi Koyanagi ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Rat Model ◽  
Nitric Oxide Synthesis ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

scholarly journals Pitavastatin: focus on safety and drug interactions

2021 ◽  
Vol 12 (1) ◽  
pp. 48-53
Author(s):  
Larisa O. Minushkina ◽  
Dmitry A. Zateyshchikov
Keyword(s):  
Diabetes Mellitus ◽  
Drug Interactions ◽  
Lipid Lowering ◽  
Efficacy And Safety ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Pitavastatin is a drug from the group of HMG-CoA reductase inhibitors, which has good lipid-lowering efficacy and has no significant effect on the risk of diabetes mellitus. This drug is non significantly metabolized by the P450 cytochrome system, which minimizes the risk of possible drug-drug interactions. Peptide organic anionic transporter inhibitors also may affect the efficacy and safety of the drug. This review summarizes the data on the problems of drug interactions of pitavastatin.

Sign in / Sign up

Export Citation Format

Share Document